MedTrace Logo

A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria

NCT00189878 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2016-02-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether methotrexate produces significant improvement in chronic idiopathic urticaria, compared with placebo

Conditions

  • Urticaria

Interventions

DRUG

Methotrexate (drug)

Methotrexate 10 to 15 mg weekly for 8 weeks

DRUG

placebo capsules

4-6 placebo capsules - identical to capsules containing methotrexate

Sponsors & Collaborators

  • Barnsley Hospital

    lead OTHER

Principal Investigators

  • Ruth A Sabroe, FRCP, MD · Barnsley Hospital NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189878 on ClinicalTrials.gov